Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker SNDX
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Dennis G Podlesak Director | SNDX Syndax Pharmaceuticals, Inc. | 8,000 | $114.6K | 10b5-1 | Oct 29, 2026 | Form 4 ↗ 1 day later · 8,000 shares | Form 144 ↗ |
| Jul 8, 2026 | Michael Metzger Director, Officer | SNDX Syndax Pharmaceuticals, Inc. | 32,375 | $752.4K | 10b5-1 | Jul 8, 2026 | Form 4 ↗ 1 day later · 32,375 shares | Form 144 ↗ |
| Jun 12, 2026 | Botwood Nicholas A.J. Officer | SNDX Syndax Pharmaceuticals, Inc. | 31,235 | $566.7K | 10b5-1 | Jun 12, 2026 | Form 4 ↗ same day · 65,515 shares | Form 144 ↗ |
| Jun 11, 2026 | Botwood Nicholas A.J. Officer | SNDX Syndax Pharmaceuticals, Inc. | 34,280 | $609.4K | 10b5-1 | Jun 11, 2026 | Form 4 ↗ 1 day later · 65,515 shares | Form 144 ↗ |
| Jun 1, 2026 | Keith A. Goldan Officer | SNDX Syndax Pharmaceuticals, Inc. | 1,177 | $22.4K | — | Jun 1, 2026 | Form 4 ↗ 1 day later · 1,177 shares | Form 144 ↗ |
| Jun 1, 2026 | Michael A. Metzger Officer, Director | SNDX Syndax Pharmaceuticals, Inc. | 6,847 | $130.0K | — | Jun 1, 2026 | Form 4 ↗ 1 day later · 6,847 shares | Form 144 ↗ |
| Feb 9, 2026 | Michael A. Metzger Officer, Director | SNDX Syndax Pharmaceuticals, Inc. | 17,159 | $360.8K | — | Feb 9, 2026 | Form 4 ↗ 1 day later · 17,159 shares | Form 144 ↗ |
| Feb 9, 2026 | Keith A. Goldan Officer | SNDX Syndax Pharmaceuticals, Inc. | 3,410 | $71.7K | — | Feb 9, 2026 | Form 4 ↗ 1 day later · 3,410 shares | Form 144 ↗ |
| Feb 6, 2026 | Michael A. Metzger Officer, Director | SNDX Syndax Pharmaceuticals, Inc. | 7,412 | $152.8K | — | Feb 6, 2026 | Form 4 ↗ same day · 7,412 shares | Form 144 ↗ |
| Feb 6, 2026 | Keith A. Goldan Officer | SNDX Syndax Pharmaceuticals, Inc. | 2,082 | $42.9K | — | Feb 6, 2026 | Form 4 ↗ same day · 2,082 shares | Form 144 ↗ |
| Sep 8, 2025 | Michael Metzger Director, Officer | SNDX Syndax Pharmaceuticals, Inc. | 157,307 | $2.7M | 10b5-1 | Sep 8, 2025 | Form 4 ↗ same day · 157,307 shares | Form 144 ↗ |
| Aug 18, 2025 | Dennis G Podlesak Director | SNDX Syndax Pharmaceuticals, Inc. | 14,400 | $226.7K | 10b5-1 | Aug 18, 2025 | Form 4 ↗ same day · 38,400 shares | Form 144 ↗ |
| Aug 14, 2025 | Dennis G Podlesak Director | SNDX Syndax Pharmaceuticals, Inc. | 43,200 | $581.0K | 10b5-1 | Aug 14, 2025 | Form 4 ↗ 4 days later · 57,600 shares | Form 144 ↗ |
| Jul 16, 2025 | Keith A. Goldan Officer | SNDX Syndax Pharmaceuticals, Inc. | 1,296 | $12.0K | — | Jul 16, 2025 | Form 4 ↗ 2 days later · 1,296 shares | Form 144 ↗ |
| Jul 16, 2025 | Michael A. Metzger Officer, Director | SNDX Syndax Pharmaceuticals, Inc. | 7,534 | $70.0K | — | Jul 16, 2025 | Form 4 ↗ 2 days later · 7,534 shares | Form 144 ↗ |
| Jul 10, 2025 | Gallagher Neil Officer | SNDX Syndax Pharmaceuticals, Inc. | 9,679 | $89.7K | — | Jul 10, 2025 | — | Form 144 ↗ |
| Mar 4, 2025 | Michael Metzger Officer | SNDX Syndax Pharmaceuticals, Inc. | 13,888 | $215.0K | 10b5-1 | Mar 4, 2025 | Form 4 ↗ 2 days later · 7,814 shares | Form 144 ↗ |
| Feb 10, 2025 | Keith A. Goldan Officer | SNDX Syndax Pharmaceuticals, Inc. | 3,777 | $58.6K | — | Feb 10, 2025 | Form 4 ↗ 2 days later · 3,777 shares | Form 144 ↗ |
| Feb 10, 2025 | Michael A. Metzger Officer, Director | SNDX Syndax Pharmaceuticals, Inc. | 13,288 | $206.0K | — | Feb 10, 2025 | Form 4 ↗ 2 days later · 13,288 shares | Form 144 ↗ |
| Feb 10, 2025 | Gallagher Neil Officer | SNDX Syndax Pharmaceuticals, Inc. | 4,618 | $71.6K | — | Feb 10, 2025 | Form 4 ↗ 2 days later · 4,618 shares | Form 144 ↗ |
| Aug 9, 2023 | Briggs Morrison Director | SNDX Syndax Pharmaceuticals, Inc. | 52,855 | $964.6K | 10b5-1 | Aug 9, 2023 | — | Form 144 ↗ |
| Aug 2, 2023 | William Meury Director | SNDX Syndax Pharmaceuticals, Inc. | 83,000 | $1.7M | 10b5-1 | Aug 2, 2023 | — | Form 144 ↗ |
| Jul 10, 2023 | Briggs Morrison Director | SNDX Syndax Pharmaceuticals, Inc. | 52,855 | $1.1M | 10b5-1 | Jul 10, 2023 | — | Form 144 ↗ |
| Jun 9, 2023 | Briggs W Morrison Director | SNDX Syndax Pharmaceuticals, Inc. | 52,855 | $1.1M | 10b5-1 | Jun 9, 2023 | — | Form 144 ↗ |
| May 9, 2023 | Briggs W Morrison &Angela Hoover Morrison JT Ten Officer | SNDX Syndax Pharmaceuticals, Inc. | 52,855 | $1.1M | 10b5-1 | May 9, 2023 | — | Form 144 ↗ |
25 items, most recent first (up to 50). Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 10:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances